These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 18358909)

  • 1. Tocilizumab for rheumatoid and juvenile idiopathic arthritis.
    Bongartz T
    Lancet; 2008 Mar; 371(9617):961-3. PubMed ID: 18358909
    [No Abstract]   [Full Text] [Related]  

  • 2. Tocilizumab for systemic juvenile idiopathic arthritis.
    Hagino N; Yamaguchi K; Ohara Y
    N Engl J Med; 2013 Mar; 368(13):1256. PubMed ID: 23534567
    [No Abstract]   [Full Text] [Related]  

  • 3. Tocilizumab for systemic juvenile idiopathic arthritis.
    De Benedetti F
    N Engl J Med; 2013 Mar; 368(13):1256-7. PubMed ID: 23534566
    [No Abstract]   [Full Text] [Related]  

  • 4. A new era in the treatment of systemic juvenile idiopathic arthritis.
    Sandborg C; Mellins ED
    N Engl J Med; 2012 Dec; 367(25):2439-40. PubMed ID: 23252530
    [No Abstract]   [Full Text] [Related]  

  • 5. Tocilizumab: molecular intervention therapy in children with systemic juvenile idiopathic arthritis.
    Yokota S; Kishimoto T
    Expert Rev Clin Immunol; 2010 Sep; 6(5):735-43. PubMed ID: 20828281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.
    Yokota S; Imagawa T; Mori M; Miyamae T; Aihara Y; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
    Lancet; 2008 Mar; 371(9617):998-1006. PubMed ID: 18358927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis.
    Zhang X; Morcos PN; Saito T; Terao K
    Expert Rev Clin Pharmacol; 2013 Mar; 6(2):123-37. PubMed ID: 23473591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interlukin-6 receptor inhibitor tocilizumab: a new treatment option in rheumatoid arthritis?
    Johnson J; Wang MY
    Neurosurgery; 2008 Aug; 63(2):N8. PubMed ID: 18797345
    [No Abstract]   [Full Text] [Related]  

  • 9. Improvement of reduced serum cartilage oligomeric matrix protein levels in systemic juvenile idiopathic arthritis patients treated with the anti-interleukin-6 receptor monoclonal antibody tocilizumab.
    Nakajima S; Naruto T; Miyamae T; Imagawa T; Mori M; Nishimaki S; Yokota S
    Mod Rheumatol; 2009; 19(1):42-6. PubMed ID: 18726067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is tocilizumab an option for the treatment of arthritis?
    Doggrell SA
    Expert Opin Pharmacother; 2008 Aug; 9(11):2009-13. PubMed ID: 18627338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti-IL-6 receptor antibody].
    Nishimoto N
    Nihon Rinsho; 2005 May; 63 Suppl 5():723-7. PubMed ID: 15954436
    [No Abstract]   [Full Text] [Related]  

  • 12. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement.
    Woo P; Wilkinson N; Prieur AM; Southwood T; Leone V; Livermore P; Wythe H; Thomson D; Kishimoto T
    Arthritis Res Ther; 2005; 7(6):R1281-8. PubMed ID: 16277681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tocilizumab in rheumatoid arthritis. Interleukin 6 as a new target].
    Heinzl S
    Med Monatsschr Pharm; 2008 Dec; 31(12):450-3. PubMed ID: 19133593
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis.
    Yokota S; Miyamae T; Imagawa T; Katakura S; Kurosawa R; Mori M
    Clin Rev Allergy Immunol; 2005 Jun; 28(3):231-8. PubMed ID: 16129907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiographic improvement of damaged large joints in children with systemic juvenile idiopathic arthritis following tocilizumab treatment.
    Inaba Y; Ozawa R; Imagawa T; Mori M; Hara Y; Miyamae T; Aoki C; Saito T; Yokota S
    Ann Rheum Dis; 2011 Sep; 70(9):1693-5. PubMed ID: 21402562
    [No Abstract]   [Full Text] [Related]  

  • 16. The clinical efficacy of tocilizumab in rheumatoid arthritis.
    Mircic M; Kavanaugh A
    Drugs Today (Barc); 2009 Mar; 45(3):189-97. PubMed ID: 19436841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis.
    Okuda Y; Takasugi K
    Arthritis Rheum; 2006 Sep; 54(9):2997-3000. PubMed ID: 16947531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient.
    Tsang AC; Roth J; Gottlieb C
    Ocul Immunol Inflamm; 2014 Apr; 22(2):155-7. PubMed ID: 24377416
    [No Abstract]   [Full Text] [Related]  

  • 19. Tocilizumab for the treatment of juvenile idiopathic arthritis.
    Decelle K; Horton ER
    Ann Pharmacother; 2012 Jun; 46(6):822-9. PubMed ID: 22589451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sarilumab: First Global Approval.
    Scott LJ
    Drugs; 2017 Apr; 77(6):705-712. PubMed ID: 28290137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.